Healthcare Finance News (9/18, Morse) says, “Ahead of a hearing on pharmacy benefit managers (PBMs) before the House Committee on Oversight and Accountability on Tuesday, PhRMA released Nephron Research that contends PBMs are driving up profits and drug prices through fees.” The PBMs “demand double the amount of fees today than they did five years ago, according to the report released Monday.” To address the issue, “PhRMA recommends that PBM compensation no longer be tied to the price of medicines and they should instead receive a flat fee.” Additionally, “PBMs should share savings directly with patients so they don’t pay more than their insurer pays, PhRMA said.”
Related Links:
— “PBMs are driving up drug prices through fees, PhRMA report claims,”Susan Morse, Healthcare Finance News, September 18, 2023